Investigators from Pfizer Zero in on Clinical Trials and Studies (A Phase 1 Open Label Study To Assess the Human Mass Balance and Metabolite Profile of 14c-fosmanogepix, a Novel Gwt-1 Inhibitor In Healthy Male Participants).

A study conducted by investigators from Pfizer in New York City focused on the clinical trials and studies of fosmanogepix (FMGX), a novel antifungal drug. The study aimed to determine the disposition and metabolism of FMGX using C-14-radiolabeled FMGX. The results showed that FMGX elimination occurs through renal and hepatic routes, with extensive metabolism observed. No serious adverse events were reported, and the study concluded that FMGX was eliminated equally through renal and hepatic routes. This research provides valuable insights into the pharmacokinetics and metabolism of FMGX in healthy male participants. [Extracted from the article]